Nov 19 (Reuters) - Bayer AG :
* STRENGTHENS CARDIOVASCULAR PORTFOLIO WITH CYTOKINETICS' AFICAMTEN IN JAPAN
* EXCLUSIVE LICENSE AGREEMENT WITH CYTOKINETICS TO DEVELOP AND COMMERCIALIZE AFICAMTEN IN JAPAN
* CYTOKINETICS WILL RECEIVE APPROXIMATELY EUR 70 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS
* IS ELIGIBLE TO RECEIVE UP TO EUR 490 MILLION IN COMMERCIAL MILESTONE PAYMENTS WITH TIERED ROYALTIES ON FUTURE SALES
* HIGHLY STRATEGIC FIT ADDING TO BAYER'S COMMERCIAL FOOTPRINT IN SPECIALTY CARDIOLOGY
Source text: Further company coverage:
((frankfurt.newsroom@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。